GleamWall
中文EN

ONMD OneMedNet Corp

Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 1849380 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY365.1%
TTM net income YoY-412.3%
TTM EPS YoY-14,000.0%
Revenue 3-yr CAGR33.7%
Net income 3-yr CAGR—

Margins

Gross margin-49.7%
Operating margin-440.0%
Net margin-452.9%
FCF margin-285.4%
EBITDA margin-438.6%

Returns

ROE—
ROA-506.7%
ROIC (approx.)—
Asset turnover1.12x

Leverage & solvency

Liabilities / assets277.5%
Debt / equity—
Current ratio0.38x
Interest coverage-289.40x

Cash quality & payout

Operating cash flow / net income0.63x
Accruals ratio-188.2%
Payout ratio—
Capex / revenue0.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$1.02M$292,000$96,000$891,000$177,000$155,000$137,000$26,000
Cost of revenue$1.39M$857,000$476,000$726,000$399,000$396,000$361,000$52,000
Gross profit-$363,000-$565,000-$380,000$165,000-$222,000-$241,000-$224,000-$26,000
R&D expense$424,000$324,000$311,000$443,000$323,000$382,000$348,000$340,000
SG&A expense$1.19M$981,000$1.48M$2.38M$1.39M$1.18M$1.36M$2.09M
Operating income-$2.23M-$2.26M-$2.55M-$3.08M-$2.23M-$2.06M-$2.22M-$2.67M
Interest expense$8,000$9,000$10,000$8,000$6,000$22,000$31,000$92,000
Net income-$2.66M-$2.17M-$2.45M-$3.14M-$741,000$2.98M-$1.90M-$2.37M
EBITDA-$2.23M-$2.26M-$2.54M-$3.07M-$2.23M-$2.03M-$2.21M-$2.64M
EPS (basic)-0.43-0.04-0.04—-0.140.07-0.06—
EPS (diluted)-0.43-0.04-0.04—-0.140.07-0.06—
Weighted avg. shares (diluted)6.15M58.02M55.32M—5.26M38.41M34.10M—
Balance sheet
Cash & equivalents$137,000$358,000$233,000$585,000$149,000$122,000$144,000$172,000
Receivables$2.27M$664,000$697,000$495,000$582,000$254,000$247,000$213,000
Current assets$2.56M$1.31M$1.46M$2.10M$1.45M$2.27M$1.63M$3.62M
PP&E, net$44,000$51,000$47,000$56,000$60,000$70,000$101,000$108,000
Total assets$2.61M$1.36M$1.51M$2.15M$1.51M$2.34M$1.73M$3.73M
Current liabilities$6.70M$4.73M$5.36M$4.83M$5.00M$6.16M$18.15M$19.23M
Short-term debt$563,000$701,000$837,000$974,000——$2.33M$9.38M
Long-term debt$99,000$132,000$176,000$220,000——$2.33M$2.32M
Total debt$662,000$833,000$1.01M$1.19M——$4.66M$11.70M
Total liabilities$7.24M$4.88M$5.59M$5.12M$5.45M$6.18M$18.28M$19.68M
Shareholders' equity-$4.63M-$3.52M-$4.08M-$2.96M-$3.94M-$3.84M-$16.55M-$15.95M
Net debt$525,000$475,000$780,000$609,000——$4.52M$11.53M
Shares outstanding6.03M57.72M52.79M5.18M49.73M46.10M30.57M27.99M
Cash flow statement
Operating cash flow-$1.42M-$1.88M-$1.54M-$1.71M-$1.41M-$2.19M-$1.85M-$2.03M
Capital expenditure$1,000$9,000$2,000$5,000$0$3,000$5,000$35,000
Free cash flow-$1.42M-$1.88M-$1.54M-$1.72M-$1.41M-$2.19M-$1.86M-$2.06M
Investing cash flow-$1,000$56,000$352,000-$51,000$1.11M-$670,000$1.92M$365,000
Financing cash flow$1.20M$1.94M$838,000$2.20M$331,000$3.03M-$94,000-$100,000
Depreciation & amortization$8,000$5,000$11,000$9,000$10,000$34,000$12,000$26,000
Stock-based compensation$458,000$463,000$431,000$1.49M$142,000$197,000$208,000$181,000

Free plan shows the latest 8 periods; Pro shows all 21 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.